These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 21802143)

  • 1. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
    Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
    Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
    Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
    Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
    J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients.
    Hosohata K; Masuda S; Katsura T; Takada Y; Kaido T; Ogura Y; Oike F; Egawa H; Uemoto S; Inui K
    Drug Metab Dispos; 2009 Apr; 37(4):821-6. PubMed ID: 19139162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
    Takahashi K; Motohashi H; Yonezawa A; Okuda M; Ito N; Yamamoto S; Ogawa O; Inui K
    Ann Pharmacother; 2004 May; 38(5):791-4. PubMed ID: 15010519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.
    Hosohata K; Masuda S; Ogura Y; Oike F; Takada Y; Katsura T; Uemoto S; Inui K
    Drug Metab Pharmacokinet; 2008; 23(2):134-8. PubMed ID: 18445994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
    Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
    J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.
    Hosohata K; Masuda S; Yonezawa A; Sugimoto M; Takada Y; Kaido T; Ogura Y; Oike F; Uemoto S; Inui K
    Drug Metab Pharmacokinet; 2009; 24(5):458-63. PubMed ID: 19881258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
    Miura M; Satoh S; Tada H; Saito M; Kagaya H; Inoue K; Sagae Y; Kanno S; Ishikawa M; Habuchi T; Suzuki T
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):605-13. PubMed ID: 17190370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of
    Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
    Miura M; Inoue K; Satoh S; Itoh Y; Kagaya H; Tada H; Tanaka Y; Habuchi T; Suzuki T
    Clin Drug Investig; 2007; 27(4):251-8. PubMed ID: 17358097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
    Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
    Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
    Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
    Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
    J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
    Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.